Abstract
Few reports have described pediatric Multidrug-resistant Tuberculosis (MDR-TB) in the former Soviet republics, despite the fact that these countries have the highest proportion of TB cases that are MDR. We aimed to examine pediatric MDR-TB in Ukraine. This retrospective cohort study included all children <18 years of age who started undergoing MDR-TB treatment between January 1, 2011 and July 31, 2016 at Kyiv City Pediatric TB Hospital. From each child’s clinical chart, we abstracted demographic and clinical data. Using Fisher’s exact test, we compared characteristics between children with microbiologically confirmed vs. probable (i.e., clinically diagnosed) MDR-TB. The study population included 20 children with a median age of 5 years. At diagnosis, 12 (60%) had intrathoracic lymphadenopathy as their only radiographic abnormality, and two (10%) were asymptomatic. Children with confirmed MDR-TB were more likely to be adolescents or have radiologic abnormalities in addition to intrathoracic lymphadenopathy. Median treatment duration was 20 months. Eighteen (90%) children were treated successfully. The remaining two were transferred to another facility, and their final outcomes were unknown. The excellent outcomes in this cohort are consistent with high treatment success rates for pediatric MDR-TB reported in other parts of the world.
Article PDF
Avoid common mistakes on your manuscript.
References
Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Pérez-Vélez CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 2014;383;1572–9.
Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis 2016;16;1193–201.
Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med 2018;15;e1002591.
Gegia M, Jenkins HE, Kalandadze I, Furin J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009–2011. Int J Tuberc Lung Dis 2013;17;624–9.
Smirnova PA, Turkova A, Nikishova EI, Seddon JA, Chappell E, Zolotaya OA, et al. Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study. Eur Respir J 2016;48;1496–9.
Swaminathan A, du Cros P, Seddon JA, Quinnell S, Bobokhojaev OI, Dusmatova Z, et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. Int J Tuberc Lung Dis 2016;20;474–8.
World Health Organization. Global Tuberculosis Report 2017. Geneva, Switzerland: World Helath Organization; 2017.
Center for Public Health of the Ministry of Health of Ukraine. Statistical TB information; 2017, available from: https://phc.org.ua/pages/diseases/tuberculosis/surveillance/statistical-information [accessed 26 Aug 2018].
Pavlenko E, Barbova A, Hovhannesyan A, Tsenilova Z, Slavuckij A, Shcherbak-Verlan B, et al. Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey. Int J Tuberc Lung Dis 2018;22;197–205.
UNAIDS. UNAIDS Data 2017: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2017, available from: http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf [accessed 26 Aug 2018].
Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. BMC Infect Dis 2017;17;129.
Lytvynenko N, Cherenko S, Feschenko Y, Pogrebna M, Senko Y, Barbova A, et al. Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing? Public Health Action 2014;4;S67–S72.
Ministry of Health of Ukraine. Order of the Ministry of Health of Ukraine No. 1091: On Approval and Implementation of Medical Technological Documents for the Standardization of Medical Aid for Tuberculosis. Kyiv, Ukraine; 2012.
Ministry of Health of Ukraine. Order of the Ministry of Health of Ukraine No. 620: On Approval and Implementation of Medical-Technological Documents on Standardization of Medical Aid for Tuberculosis. Kyiv, Ukraine; 2014.
World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 2014.
World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 2011.
Seddon JA, Perez-Velez CM, Schaaf HS, Furin JJ, Marais BJ, Tebruegge M, et al. Consensus statement on research definitions for drug-resistant tuberculosis in children. J Pediatr Infect Dis Soc 2013;2;100–9.
World Health Organization. Child growth standards: BMI-f or-age; 2018, available from: http://www.who.int/childgrowth/standards/bmi_for_age/en/ [accessed 24 Apr 2018].
World Health Organization. Growth reference 5–19 years: BMI-for-age (5–19 years); 2018, available from: http://www.who.int/growthref/who2007_bmi_for_age/en/ [accessed 24 Apr 2018].
Wiseman CA, Gie RP, Starke JR, Schaaf HS, Donald PR, Cotton MF, et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J 2012;31; 347–52.
National Institutes of Health. LiverTox: Clinical and research information on drug-induced liver injury. Severity grading in drug induced liver injury; 2017, available from: https://livertox.nih.gov/Severity.html [accessed 25 Jun 2018].
World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update. Geneva, Switzerland: World Health Organization; 2016.
Chiang SS, Furin JJ. Treatment of multidrug-resistant tuberculosis in children and adolescents. J Pediatr Infect Dis 2018;13;153–68.
Franck C, Seddon JA, Hesseling AC, Schaaf HS, Skinner D, Reynolds L. Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study. BMC Infect Dis 2014;14;426.
Wray J, Long T, Radley-Smith R, Yacoub M. Returning to school after heart or heart-lung transplantation: how well do children adjust? Transplantation 2001;72;100–6.
Ozbaran M, Yagdi T, Engin C, Ulger Z, Ozbaran B, Kose S, et al. New era of pediatric ventricular assist devices: let us go to school. Pediatr Transplant 2015;19;82–6.
WHO Regional Office for Europe. Tuberculosis country brief, 2016: Ukraine 2016; 2016, available from: http://www.euro.who.int/__data/assets/pdf_file/0004/335542/UKR_TB_Brief_0223-AM-edits-D1-20-03-17.pdf?ua=1 [accessed 16 Sept 2018].
Chiang SS, Swanson DS, Starke JR. New diagnostics for childhood tuberculosis. Infect Dis Clin N Am 2015;29;477–502.
Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis 2018;22;S3–S6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/)
About this article
Cite this article
Chiang, S.S., Sheremeta, Y., Padilla, R.S. et al. Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine. J Epidemiol Glob Health 9, 56–61 (2019). https://doi.org/10.2991/jegh.k.190225.002
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/jegh.k.190225.002